Skip to main content
. 2016 Mar 23;23(4):692–700. doi: 10.1093/jamia/ocw008

Table 3:

EGFR-mutated lung cancer patients were more likely to have ever received erlotinib and less likely to have ever received a platinum-based chemotherapy.

Lung cancer genotype +erlotinib exposure No erlotinib exposure +platinum exposure No platinum exposure
EGFR-mutated (N = 77) 70 7 27 50
EGFR wild type (N = 511) 153 358 249 262